DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myelo id Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic Syndrome Interventions:   Biological: Antineoplastic Antibody-Drug Conjugate;   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Biological: Filgrastim;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Posaconazole;   Drug: Prednisone;   Biolog ical: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Voriconazole Sponsor:   M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials